Voluson P6, Voluson P8
GE Healthcare • Radiology • 02/17/2022
Device Purpose
The Voluson P6 and P8 are versatile diagnostic ultrasound systems designed for comprehensive imaging and analysis across diverse medical specializations, with a focus on OB/GYN applications through real-time 3D/4D capabilities. Utilizing established ultrasound principles and a range of transducer technologies, these systems offer multiple imaging modes and incorporate software enhancements to improve diagnostic workflow and clinical utility.
Summary
The Voluson P6 and Voluson P8 are general-purpose diagnostic ultrasound systems designed for use by qualified healthcare professionals in hospital or medical clinic settings. These systems facilitate ultrasound imaging, measurement, display, and analysis of the human body and fluids across a wide range of clinical applications, including fetal/obstetrics, abdominal (covering renal and GYN/pelvic), pediatric, small organs (such as breast, testes, and thyroid), neonatal and adult cephalic, cardiac (both adult and pediatric), peripheral vascular, musculo-skeletal (conventional and superficial), transrectal (including urology/prostate), and transvaginal imaging. The Voluson P6/P8 systems are mobile consoles equipped with a keyboard, LCD display, and feature comprehensive networking and DICOM capabilities; they employ fundamental ultrasound technology, using various transducers like linear, curved linear, and matrix phased arrays, and support real-time 3D/4D acquisition, making them particularly suitable for OB/GYN applications. The systems offer multiple operating modes such as B-mode, M-mode, PW/CW Doppler, Color Doppler, Power Doppler, HD-Flow, Harmonic Imaging, and 3D/4D imaging. Recent updates include the migration of the IC9B-RS probe and Sonobiometry Brain software feature, alongside improvements like IDEA Assessment and IOTA ADNEX; non-clinical testing has confirmed their safety, biocompatibility, and adherence to performance standards, including specified acoustic output levels.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the image quality and diagnostic accuracy of the migrated IC9B-RS probe on the Voluson P6/P8 compare to its performance on the original Voluson SWIFT system, particularly for its intended applications?; What specific clinical benefits or diagnostic improvements are anticipated from the newly added software features like IDEA Assessment, IOTA ADNEX, and IETA Tool in obstetric and gynecological examinations?; Could the removal of the SonoMetrium feature impact any specific diagnostic workflows or capabilities previously relied upon by users, and are there alternative functionalities within the updated system to compensate for this?; What are the quantitative performance metrics (e.g., penetration depth, resolution, frame rate) for the 3D/4D imaging mode across different transducer types and clinical applications?; How do the OS and security updates enhance the system's protection against cybersecurity threats and ensure data integrity, particularly concerning DICOM transfer and patient data management?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of SaaSBOM, HBOM, VDR/VEX detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, ML-BOM, CBOM, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly